We think Roche's drug portfolio and industry-leading diagnostics conspire to create maintainable competitive advantages. As the market leader in both biotech and diagnostics, this Swiss healthcare ...

Perjeta has become one of Roche’s fastest-growing and top-selling drugs, thanks in no small part to data from the APHINITY trial which showed that adding it to Herceptin can improve disease-free ...

I tell people I feel blessed to not be diagnosed with cancer in the US. Right now pauses on federal funding, including grants ...

Breast cancer drug Phesgo’s (a fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) sales surged 62% year over year to CHF 1.7 billion. Evrysdi generated sales of CHF 1.6 ...

RHHBY records impressive sales growth in 2024 on the back of strong demand for Vabysmo, Hemlibra, Phesgo and Ocrevus.

Roche Holding AG delivered a strong set of 2024 earnings. Guidance for 2025 suggests this will be a transitional year ahead, ...

Group sales grew by 7%1 at constant exchange rates (CER; 3% in CHF), driven by strong demand for both medicines and diagnostics.Excluding COVID-19, Group sales increased by 9%.

to Perjeta, Herceptin and taxane chemotherapy. Analysts think Enhertu sales could move north of the $2 billion threshold quite quickly, and reach $4 to $5 billion at its peak, assuming it can make ...